NASDAQ:GRTS Gritstone bio (GRTS) Stock Price, News & Analysis $0.65 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.6750-Day Range$0.57▼$0.8452-Week Range$0.52▼$3.33Volume571,179 shsAverage Volume1.70 million shsMarket Capitalization$70.84 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Gritstone bio alerts: Email Address Gritstone bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside628.0% Upside$4.75 Price TargetShort InterestHealthy8.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 19 Articles This WeekInsider TradingSelling Shares$35,453 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.99) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector601st out of 936 stocksBiological Products, Except Diagnostic Industry95th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingGritstone bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGritstone bio has only been the subject of 3 research reports in the past 90 days.Read more about Gritstone bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.12% of the float of Gritstone bio has been sold short.Short Interest Ratio / Days to CoverGritstone bio has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Gritstone bio has recently decreased by 26.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGritstone bio does not currently pay a dividend.Dividend GrowthGritstone bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTS. Previous Next 1.7 News and Social Media Coverage News SentimentGritstone bio has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Gritstone bio this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for GRTS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,453.00 in company stock.Percentage Held by InsidersOnly 4.61% of the stock of Gritstone bio is held by insiders.Percentage Held by Institutions48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gritstone bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gritstone bio are expected to grow in the coming year, from ($0.99) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone bio has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gritstone bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Gritstone bio Stock (NASDAQ:GRTS)Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Read More GRTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTS Stock News HeadlinesJuly 26 at 5:30 PM | prnewswire.comGritstone bio, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before August 6, 2024 to Discuss Your Rights - GRTSJuly 26 at 11:13 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Gritstone bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRTSJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 11:00 AM | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Gritstone bio, Inc. (GRTS)July 26 at 5:45 AM | prnewswire.comAugust 6, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GRTSJuly 25 at 5:56 PM | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRTSJuly 25 at 12:30 PM | globenewswire.comLevi & Korsinsky Notifies Shareholders of Gritstone bio, Inc.(GRTS) of a Class Action Lawsuit and an Upcoming DeadlineJuly 25 at 10:35 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GritstoneJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 5:45 AM | prnewswire.comGritstone bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 6, 2024 to Discuss Your Rights - GRTSJuly 25 at 2:38 AM | prnewswire.comGritstone Bio Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRTSJuly 24 at 1:44 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Gritstone bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRTSJuly 24 at 10:00 AM | prnewswire.comGRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 24 at 7:00 AM | globenewswire.comGritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)July 23, 2024 | globenewswire.comGRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 22, 2024 | globenewswire.comGritstone bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – GRTSJuly 22, 2024 | prnewswire.comGritstone bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GRTSJuly 22, 2024 | prnewswire.comGritstone bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GRTSSee More Headlines Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTS CUSIPN/A CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$7.00 Low Stock Price Target$3.00 Potential Upside/Downside+628.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-138,490,000.00 Net Margins-926.13% Pretax Margin-926.13% Return on Equity-232.42% Return on Assets-79.96% Debt Debt-to-Equity Ratio2.89 Current Ratio2.00 Quick Ratio2.00 Sales & Book Value Annual Sales$16.34 million Price / Sales4.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.21Miscellaneous Outstanding Shares108,570,000Free Float103,564,000Market Cap$70.84 million OptionableOptionable Beta0.50 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Andrew R. Allen BCh (Age 58)BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director Comp: $1.01MMr. Erin E. Jones M.S. (Age 52)Executive VP & COO Comp: $689.87kDr. Karin Jooss Ph.D. (Age 59)Executive VP and Head of Research & Development Comp: $748.2kMs. Vassiliki Economides (Age 44)Executive VP & CFO Mr. James ChoChief Accounting OfficerMr. George E. MacDougallDirector of Investor Relations & Corporate CommunicationsMs. Stacy ProctorExecutive VP & Chief People OfficerDr. Matthew J. Hawryluk M.B.A. (Age 46)Ph.D., Executive VP & Chief Business Officer More ExecutivesKey CompetitorsAtara BiotherapeuticsNASDAQ:ATRATenaya TherapeuticsNASDAQ:TNYAZura BioNASDAQ:ZURAMolecular PartnersNASDAQ:MOLNMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 1,030,952 shares on 5/17/2024Ownership: 0.950%Tidal Investments LLCBought 24,536 shares on 5/17/2024Ownership: 0.023%Redmile Group LLCSold 117,530 shares on 5/16/2024Ownership: 5.301%Andrew R AllenSold 24,263 sharesTotal: $18,197.25 ($0.75/share)Erin JonesSold 13,749 sharesTotal: $10,311.75 ($0.75/share)View All Insider TransactionsView All Institutional Transactions GRTS Stock Analysis - Frequently Asked Questions How have GRTS shares performed this year? Gritstone bio's stock was trading at $2.04 on January 1st, 2024. Since then, GRTS stock has decreased by 68.0% and is now trading at $0.6525. View the best growth stocks for 2024 here. How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $5.90 million. Gritstone bio had a negative trailing twelve-month return on equity of 232.42% and a negative net margin of 926.13%. What is Andrew Allen's approval rating as Gritstone bio's CEO? 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Gritstone bio IPO? Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Gritstone bio? Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN) and Enerplus (ERF). This page (NASDAQ:GRTS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gritstone bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
